Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 3Terminated 2Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Leukemia, Myeloid, Acute 17Myelodysplastic Syndromes 8Recurrence 2Leukemia, Myelomonocytic, Chronic 2Triple Negative Breast Neoplasms 1Spinocerebellar Degenerations 1Sarcoma 1Pathologic Complete Response 1Ovarian Neoplasms 1Neoplasms, Germ Cell and Embryonal 1Neoplasm, Residual 1Melanoma 1Medulloblastoma 1Lymphoma 1Leukemia 1Graft vs Host Disease 1Ependymoma 1Colorectal Neoplasms 1Central Nervous System Neoplasms 1Carcinoma, Renal Cell 1Breast Neoplasms 1

Interventions

Oxaliplatin 20Fluorouracil 20Leucovorin 19Bevacizumab 16Cetuximab 13Irinotecan 12Capecitabine 8regorafenib 5Radiotherapy 5Nivolumab 5Drug Therapy 5aflibercept 4Radiosurgery 4Neoadjuvant Therapy 4Magnetic Resonance Spectroscopy 4Chemotherapy, Adjuvant 4Biopsy 4pembrolizumab 3durvalumab 3atezolizumab 3Specimen Handling 3Folfox protocol 3Cyclophosphamide 3trifluridine tipiracil drug combination 2tremelimumab 2tislelizumab 2poly(I).poly(c12,U) 2futuximab 2fludarabine 2avelumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Colorectal Neoplasms × Azacitidine × Clear all
NCT03182894 2018-08-28

Epacadostat in Combination With Pembrolizumab and Azacitidine in Subjects With Metastatic Colorectal Cancer

University of Pittsburgh

Phase 1/2 Withdrawn
Gastrointestinal

Spinocerebellar Degenerations, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡